Scientific advice and protocol assistance
Table of contents
- How scientific advice works
- When scientific advice is most useful
- Types of questions addressed
- Questions outside the scope of scientific advice (new)
- Protocol assistance
- Scientific advice on medicine repurposing
- Scientific advice on post-authorisation safety studies (PASS)
- Parallel scientific advice with the United States
- Parallel consultations from regulators and HTA bodies
- Scientific advice on biosimilars
- Fees and fee reductions
- Medicines intended for a disease causing public health emergency
- Free rapid scientific advice for COVID-19 treatments or vaccines
- Why following scientific advice does not guarantee marketing authorisation
- What EMA publishes on outcomes of scientific advice
The European Medicines Agency (EMA) can provide medicine developers advice on the most appropriate way to generate robust evidence on a medicine's benefits and risks. EMA provides scientific advice to support the timely and sound development of high-quality, effective and safe medicines, for the benefit of patients.
At any stage of a medicine's development, a developer can ask guidance and direction from EMA on the best methods and study designs to generate robust information on how well a medicine works and how safe it is, regardless of whether the medicine is eligible for the centralised authorisation procedure or not.
Scientific advice helps to ensure that developers perform the appropriate tests and studies, so that no major objections regarding the design of the tests are likely to be raised during the evaluation of the marketing authorisation application. This also helps avoid patients taking part in studies that will not produce useful evidence.
For human medicines, scientific advice and protocol assistance are given by the Committee for Medicinal Products for Human Use (CHMP) on the recommendation of the Scientific Advice Working Party (SAWP).
For information on how to request scientific advice from EMA, see Requesting scientific advice or protocol assistance from EMA.
EMA is currently experiencing some delays in processing scientific advice requests.
EMA is putting in place measures to mitigate these delays and is liaising closely with the companies concerned.
Applicants can contact EMA for more information on expected timelines before submitting a request, by writing to email@example.com.
EMA gives scientific advice by responding to specific questions posed by the medicine developer on the development of a particular medicine.
The developer of a medicine presents the way it plans to develop its medicine and identifies questions and possible solutions. EMA then gives advice on the developer’s proposals.
Scientific advice is prospective in nature. EMA does not pre-evaluate the results of the studies and in no way concludes on whether the benefits of the medicine outweigh the risks.
- they are developing an innovative medicine and there appears to be no or insufficient relevant detail in EU guidelines or guidance documents, or in Pharmacopoeia monographs, including draft documents or monographs released for consultation;
- they are developing new or repurposed medicines targeting (re)emerging pathogens for which there is an unmet medical need but insufficient or no guidance is available;
- the developer chooses to deviate from scientific guidelines in its development plan;
- the medicine developer has limited knowledge about medicine regulation, such as some academic groups or micro, small and medium sized enterprises (SMEs).
Medicine developers can request scientific advice or protocol assistance either during the initial development of a medicine before submission of a marketing authorisation application or later on, during the post-authorisation phase.
Questions during scientific advice can relate to:
- quality aspects (e.g. manufacturing, chemical, pharmaceutical and biological testing of the medicine);
- non-clinical aspects (e.g. toxicological and pharmacological tests designed to show the activity of the medicine in the laboratory);
- clinical aspects (e.g. appropriateness of studies in patients or healthy volunteers, selection of endpoints, i.e. how best to measure effects in a study, post-authorisation activities including risk management plans);
- methodological issues (e.g. statistical tests to use, data analysis, modelling and simulation);
- overall development strategy (e.g., conditional marketing authorisation, bridging strategy for generics, safety database), significant benefit for maintaining orphan designation, and paediatric developments.
Examples of questions
Questions about the topics below are outside the scope of scientific advice:
- Compassionate use, advanced therapy medicinal product (ATMP) classification, PRIME eligibility, and accelerated assessment
- Adequacy of planned paediatric studies or an overall development plan to support a paediatric indication, which EMA addresses via a PIP submission
- Changes to the key elements of Paediatric Investigation Plan (PIP) measures and paediatric waivers or deferrals, which EMA addresses via a paediatric procedure
- Matters of a purely regulatory nature (please use the ‘Submission Details’ field in your submission via the IRIS portal)
- Adequacy of existing data for assessment of a regulatory application (e.g. a clinical trial application or marketing authorisation application). However, please include existing data expected to inform the discussion of questions on further development steps in the scientific advice briefing documentation
Examples of questions
- the demonstration of significant benefit within the scope of the designated orphan indication;
- similarity or clinical superiority over other medicines. This is relevant if other orphan medicinal products exist that might be similar to the product concerned and which have market exclusivity in the same indication.
Through a pilot project, EMA and national competent authorities can offer tailored scientific advice to not-for-profit organisations and academics (institutions and individuals) on repurposing an authorised medicine for a new indication.
The aim is to help gather or generate enough evidence to support a new indication with important public health benefits for a medicine whose marketing authorisation holder is otherwise unlikely to undertake the necessary research and regulatory steps.
This provides a way of making new treatment options available to patients if it leads to the authorisation of the new indication.
Scientific advice fees are waived automatically for eligible academic sponsors repurposing a medicine for an orphan condition. Fees will also be waived for a subset of other applicants based on the expected public health benefits and strength of the evidence in their application.
The deadline to apply was 28 February 2022
More information including eligibility criteria is available in the documents below.
Question and Answers on repurposing pilot project on proposal for framework to support not-for-profit organisations and academia in repurposing authorised medicines (PDF/333.43 KB)
First published: 28/10/2021
Last updated: 04/02/2022
Submission form - Repurposing pilot project for authorised medicines (DOCX/137.24 KB)
First published: 28/10/2021
Last updated: 20/01/2022
EMA encourages medicine developers to seek scientific advice for PASS protocols. This voluntary, optional procedure will help to improve the design of studies meant to collect further information on a medicine's safety once it is on the market.
EMA ran a 12-month pilot for this procedure between July 2015-2016.
For more information, see:
- Question on 'Scientific advice for safety studies' on our page Post-authorisation safety studies: questions and answers.
General principles: European Medicines Agency-Food and Drug Administration parallel scientific advice (PDF/150.31 KB)
First published: 22/07/2009
Last updated: 18/08/2021
Timeline: European Medicines Agency-FDA parallel scientific advice (PDF/107.64 KB) (updated)
First published: 19/05/2017
Last updated: 02/02/2023
EMA offers consultations in parallel with European Network for Health Technology Assessment (EUnetHTA) as of July 2017. This aims to allow medicine developers to obtain feedback from regulators and HTA bodies on their evidence-generation plans to support decision-making on marketing authorisation and reimbursement of new medicines at the same time.
The procedure is a single gateway for parallel consultations with EMA, EUnetHTA and HTA bodies on their evidence-generation plans.
Consultations can take place before or after the product is made available on the market. The objective is to help generate optimal and robust evidence that satisfies the needs of both regulators and HTA bodies.
This initiative replaces the parallel scientific advice procedure by EMA and HTA bodies which required medicine developers to contact Member States' HTA bodies individually.
For more information, see Parallel consultation with regulators and health technology assessment bodies.
EMA offers tailored scientific advice on development programmes of new biosimiliar medicines.
The tailored procedure advises developers on the studies they should conduct, based on a review of the quality, analytical and functional data they already have available.
The tailored scientific advice procedure is open to all types of biosimilars and companies are encouraged to request a pre-submission meeting to review the suitability of the data package. Applicants should note that the SAWP will need an extra month in addition to normal scientific advice timelines to review applications.
EMA first introduced the tailored procedure as a pilot project in 2017. A report on the pilot phase is available below.
Tailored Scientific advice to support step-by-step development of new biosimilars (PDF/103.56 KB)
First published: 16/12/2016
Last updated: 14/10/2021
Tailored Scientific Advice for biosimilar development: report on the experience from the pilot (2017-2020) (PDF/168.38 KB)
First published: 14/10/2021
EMA charges a fee for scientific advice, which varies depending on the scope of the advice.
Reductions apply for certain types of medicines and applicants, including a 75% fee reduction for medicines for orphan medicines and a 90% fee reduction for SMEs.
A full waiver applies by default to scientific advice applications on clinical trials and clinical trials protocols for medicines intended to treat, prevent or diagnose a declared public health emergency.
Applicants from the academic sector are eligible to receive free protocol assistance for developing orphan medicines as of 19 June 2020. For more information see Academia and Fees payable to the European Medicines Agency.
EMA has a dedicated Emergency Task Force (ETF) to support its Committee for Medicinal Products for Human Use (CHMP) in providing scientific advice for new or repurposed human medicines that are intended to treat, prevent or diagnose a disease causing a declared public health emergency.
On a case-by-case basis, the ETF also provides advice on medicines targeting selected pathogens that can potentially cause a public health emergency.
EMA encourages developers of such medicines to contact the Agency early if they are interested in the following procedures:
- Early guidance on medicine development plan (when the plan is not yet suitable for formal scientific advice)
- Requesting scientific advice
- Applying for a marketing authorisation
They can contact EMA by writing to PHEearlyinteractions@ema.europa.eu.
Early contact is particularly important during a declared public health emergency.
When submitting a request for scientific advice, developers should indicate in their application form in which Member State(s) they intend to run clinical trials. The ETF requires this information because it involves clinical trial experts from these Member State(s) in preparing the scientific advice, in order to facilitate approval of the trial later in the process.
The procedure generally follows an accelerated timetable.
This includes COVID-19 medicines, which follow the same rules. For more information, see Free rapid scientific advice for COVID-19 treatments or vaccines.
For information on facilitating clinical trials, see COVID-19 guidance: Research and development: Clinical trials for COVID-19 medicines.
Since 2020, EMA has applied a rapid scientific advice procedure for potential COVID-19 treatments and vaccines, which is free of charge and accelerated where possible.
The rapid procedure reduces review time to a maximum of 20 days (from 40-70 days), with no pre-specified submission deadlines. The scientific advice is provided by the CHMP based on the recommendation of the Emergency Task Force (ETF).
In addition, flexibility can be agreed on a case-by-case basis on the type and extent of the briefing dossier.
These aspects are in line with the Regulation on EMA's Reinforced Role (Regulation (EU) 2022/123).
EMA encourages developers interested in requesting rapid scientific advice to contact EMA as soon as possible, to discuss their strategy for evidence-generation.
EMA and the ETF can provide early guidance to developers whose development plan is not yet suitable for formal rapid scientific advice.
For this type of support please contact EMA via the phesupportCT@ema.europa.eu.
- Scientific advice and protocol assistance: Medicines intended for a disease causing public health emergency
- Guidance for medicine developers and companies on COVID-19: Accelerated procedures for COVID-19 treatments and vaccines
- EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines
- Decision of the Executive Director on fee reductions for scientific advice requests on products for the prevention and/or treatment of COVID-19
Scientific advice and the assessment of the benefits and risks of a medicine are different by nature.
Scientific advice looks at how a medicine should be tested in studies to generate robust evidence, while the assessment at the time of marketing authorisation looks at the evidence generated to determine whether the medicine’s benefits outweigh its risks, regardless of any advice previously given.
Scientific advice can make the evaluation of a medicine easier and quicker because the evidence is likely to be more robust, appropriate and complete, but it does not affect the stringent assessment of safety and efficacy.
During the development and assessment phases, the detailed advice given to a medicine developer is not made public. This is because disclosing information at this stage may undermine research and development efforts and discourage research in new medicines.
However, information is made available after a medicine obtains marketing authorisation. All medicines whose assessment report was finalised after 1 January 2019 include a summary of the developer’s questions and key elements of EMA's advice and whether or not the developer complied with this advice within the assessment report.
During a declared public health emergency, EMA publishes a list of medicines that have received informal or formal advice from the CHMP and the ETF.
In addition, the full advice can be made available upon request. For more information, see Access to documents.